Marks George News Today

Intermittent theta burst stimulation for refractory depression failed to outperform rTMS. Nevertheless, the results are valuable because they show the potential merit of an individualized approach.

It is time for the mental health industry to embrace modern and advanced technology to help treatment-resistant patients.

/PRNewswire/ -- MAPS Public Benefit Corporation ("MAPS PBC"), a private biopharmaceutical company dedicated to the development and commercialization of...

MAPS PBC Announces Frontiers in Psychiatry Published First Study to Evaluate Neural Impact of MDMA-Assisted Therapy in Patients with PTSD - read this article along with other careers information, tips and advice on BioSpace

The FDA has cleared the SAINT Neuromodulation System for the treatment of MDD in adults who have failed prior antidepressant medications.

The FDA has cleared the SAINT Neuromodulation System for the treatment of MDD in adults who have failed prior antidepressant medications.

Magnus Medical, Inc., a medical device company and developer of brain stimulation technology for treatment of neuropsychiatric disorders, today announced it received 510(k) clearance from the U.S. Food & Drug Administration for the SAINTTM Neuromodulation System for the treatment of major depressive disorder (MDD) in adults who have failed to achieve satisfactory improvement from prior antidepressant medications in the current episode.

Why does walking so de-stress you and boost your mood so well? Why does calming your mind improve immunity? The vagus nerve is a key part of the explanation.

A large-scale retrospective study showed that hospitalized patients undergoing ECT had lower rates of suicide and comparable risk of serious medical events as peers receiving psychotherapy and medication.